The FDA accepted a resubmitted new drug application for reproxalap, a first-in-class investigational topical therapy for dry ...

Berlin: Bayer has announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug ...

GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...

The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque ...

Researchers at the National University of Singapore (NUS) have found new applications of magnetic field therapy with ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

In a complete response letter, the FDA indicates the drug trial is not an adequate, well-controlled clinical investigation, ...

Small molecule drugs are low-molecular-weight, organic compounds used to treat a wide range of conditions. Here's what you should know.

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.